SCA
JAZZ icon

SAC Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

SAC Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,533
Closed -$351K – 517
2014
Q1 		$351K Sell
2,533
-6,645
-72% -$1M ﹤0.01% 1338
2013
Q4 		$1.16M Buy
9,178
+6,498
+242% +$672K 0.01% 865
2013
Q3 		$246K Buy
+2,680
New +$216K ﹤0.01% 1500

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's JAZZ Position: Q2 2014 in Review

SAC Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2014, closing a stake of 2,533 shares — an estimated $351K sold.

SAC Capital Advisors first reported a position in JAZZ in Q3 2013 and held it in 3 quarters. The position peaked at $1.16M in Q4 2013. 305 funds tracked by Wall St. Rank hold JAZZ as of Q2 2014.

  • SAC Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,533 Jazz Pharmaceuticals shares in Q2 2014, an estimated $351K.
  • SAC Capital Advisors first reported a position in Jazz Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Jazz Pharmaceuticals position peaked at $1.16M in Q4 2013.
  • 305 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.